Default company panoramic image
Thumb logo

Camras Vision

The Camras Shunt is a device that provides the first-ever personalized pressure control to attain the highest level of efficacy in stopping glaucoma progression

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Durham, NC, USA
  • Currency USD
  • Founded October 2010
  • Employees 3
  • Website camrasvision.com

Company Overview

Camras Vision is an ophthalmic medical device company developing a patented new technology for the 67 million glaucoma sufferers. Ophthalmologists are faced with limited surgical treatments due to their instability and unpredictability in controlling glaucoma. As a result, 1 out of 10 patients still lose their vision even when properly treated. Camras Vision wishes to address these problems with their device, the Camras Shunt.

Management Team

  • Roberto has previous experience as a Manager for Deloitte where he acquired detailed knowledge in developing and improving operational processes, managing a multi-billion dollar project, selling new services to clients, and managing projects domestically and internationally.

  • Lucinda Camras has been working in aqueous humor dynamics and biomedical engineering for almost a decade. She has five patents issued or pending in the ophthalmology field. She also served as the Dir. of Scientific Research at ACE Vision Group, a start-up ophthalmic company going through clinical trials overseas. Lucinda has presented at numerous conferences, published in reputable ophthalmic journals, and received various awards.

  • Ray Krauss has 30+ years executive experience in the medical device industry (R&D, Business Dev., Regulatory, QA and General Management). His experience includes both PMA and 510(k) devices as well as working in private & public companies, ranging from 2 person startups to 200+. He has worked in numerous startups, raised financing from Angel Investors and Venture Capital firms, and led the sale of two different companies to strategic partners.